Background. Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effective strategy to prevent acquisition of human immunodeficiency virus (HIV) infection. It is important to monitor PrEP uptake at the national level to increase our understanding of trends in its utilization, but national HIV surveillance data do not include PrEP uptake. Our objective was to develop feasible methods to estimate PrEP uptake and to estimate uptake each year among commercially insured persons during 2010-2014.
The number of new human immunodeficiency virus (HIV) infections in the United States has decreased from about 130 000 per year in the mid-1980s to an estimated 45 000 new HIV diagnoses in 2014 [1] . The decrease in the number of new HIV infections can be largely attributed to the use of antiretroviral therapy, which can suppress viral load, improving the health and longevity of HIV-infected persons [2] and decreasing HIV transmission [3] . During the past decade, the number of new HIV diagnoses has remained stable [4] , despite the availability of antiretroviral therapy and behavioral interventions. The rate has been increasing in young men who have sex with men (MSM) and especially young black MSM [1] . HIV preexposure prophylaxis (PrEP) is a new biomedical HIV prevention tool that can decrease the risk of acquiring an HIV infection, and offers the potential to decrease the incidence of HIV infections in the United States.
PrEP with daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) was found to be highly effective in reducing the risk of HIV acquisition among MSM, heterosexual men and women, and persons who inject drugs [5] [6] [7] . PrEP with TDF-FTC was approved by the US Food and Drug Administration in 2012 [8, 9] , and the Centers for Disease Control and Prevention (CDC) published comprehensive clinical practice guidelines in 2014 [10] . Before this, the CDC issued interim PrEP guidelines for MSM in 2011 [11] , heterosexual men and women in 2012 [12] , and persons who inject drugs in 2013 [8] .
The impact of PrEP in decreasing HIV incidence depends on its uptake among persons at substantial risk of HIV acquisition [13] and on their adherence to daily dosing [13, 14] . It is important to monitor PrEP uptake to increase our understanding of trends in its utilization and to support the development of targeted implementation programs and policies to increase access for persons in populations most heavily affected by the HIV epidemic. Because PrEP use is not included in CDC's HIV surveillance system, the most convenient and feasible method to estimate uptake is analyses of administrative billing claims databases. In this study, we analyzed a large commercial insurance claims database to estimate PrEP uptake among persons with private health insurance in the United States during 2010-2014.
METHODS

Data Source
We analyzed data from the 2009-2014 MarketScan Commercial Claims and Encounters database, a large health insurance database managed by Truven Health Analytics. The database contained information for approximately 43-53 million persons each year who had commercial employer-sponsored health insurance in the United States. The data included deidentified, individual-level information on patient demographics, including age, sex, geographic region of the residence (and whether the person resided in the metropolitan statistical area), and health plan enrollment details, along with health services claims data with patients' diagnoses, procedures, and prescriptions.
Algorithm to Identify PrEP Users
Specific diagnostic or procedural codes for PrEP were not available. Therefore, we developed an algorithm to identify persons prescribed TDF-FTC for PrEP that used a person's medical and pharmacy claims data (Figure 1) . In a given year, we selected persons aged ≥16 years who had ≥1 TDF-FTC prescription. We defined the date of the first TDF-FTC prescription claim as the persons' index date for that year. In addition to HIV PrEP, TDF-FTC can also be used to treat HIV or hepatitis B infection or as HIV postexposure prophylaxis (PEP). To identify persons prescribed TDF-FTC for PrEP, we applied several exclusion criteria.
First, we excluded persons who had any indicator of HIV infection at any time before or within 30 days after the index date. Indicators for HIV infection included (1) ≥1 outpatient claim with an HIV diagnosis and (2) ≥1outpatient pharmacy claim for antiretroviral drugs for HIV treatment other than TDF-FTC. We included all retrospective clinical and prescription data for 1 year before the index data, to exclude persons who might have had an indicator of HIV or hepatitis B infection in the prior year. As a result, each person's clinical and prescription claims were included for ≥12 months before the index TDF-FTC date, and no more than 24 months (eg, persons with a TDF-FTC index data in December 2014 would have retrospective claims data to January 2013). We allowed a 30-day postindex window because billing claims for clinical encounters might have been submitted later than the prescription fill date.
Second, we excluded persons who had an indicator of hepatitis B infection at any time before or within 30 days after the index date. Indicators for hepatitis B infections included (1) ≥1 outpatient claim with a hepatitis B diagnosis and (2) ≥1 outpatient pharmacy claim for prescription drugs for hepatitis B treatment other than TDF-FTC.
Third, we excluded persons who were prescribed TDF-FTC for PEP. Although the clinical guidelines recommend that an antiretroviral regimen for PEP should be prescribed for 28 days [15] , some clinicians might have prescribed PEP for 30 days. Therefore, we assumed that TDF-FTC prescribed for ≤30 days was used for PEP rather than PrEP.
For persons with only 1 TDF-FTC prescription claim during the year, we included them as PrEP users if their drug supply exceeded 30 days. For patients with multiple TDF-FTC prescription claims, we evaluated each medication fill gap-the time between the end of the prescribed TDF-FTC supply and the refill date of the next supply-and defined TDF-FTC use with a gap of ≤ 14 days as a "continuous PrEP prescription. " We considered persons whose continuous TDF-TFC prescriptions exceeded 30 days to be PrEP users.
We used International Classification of Diseases, Ninth Revision, Clinical Modification codes and National Drug Codes to identify patients' diagnoses and prescriptions used in the algorithm (Supplementary Appendix Table 1 ) . In any given year, persons with TDF-FTC prescriptions who were not excluded with our algorithm were considered PrEP users.
Statistical Analysis
We used national weighting variables included in the MarketScan database to generate national estimates of the number of persons prescribed PrEP. We estimated the weighted prevalence of persons who used PrEP among all persons aged ≥16 years with commercial health insurance, and the prevalence per million for each year. Cochran Armitage trend tests were conducted to determine whether the proportions of PrEP uptake changed significantly over time. Analyses were performed using SAS Version 9.3 (SAS Institute).
Sensitivity Analysis
We did not require persons in our study sample to be continuously enrolled in their health plans during the 5-year study period. Continuous enrollment criteria are commonly used in analyses using a health services claims database to ensure consistent data feed. However, it was important for our study to use less restricted criteria to identify all possible PrEP users in the database to generate national estimates. If persons did not enroll for a long enough period before the TDF-FTC index date, we might have misclassified them as PrEP users if they had unobserved medical records with indicators for HIV or hepatitis B infection. Despite an average enrollment period that preceded the TFD-FTC index date by 10.5-11.6 months for persons in our study sample, approximately 15% of these persons had a short enrollment period (< 3 months) before the TDF-FTC index date. To examine the magnitude of a possible misclassification bias, we performed sensitivity analyses by limiting the study sample to various lengths of continuous enrollment (3, 6, or 12 months before the index date) and compared the percentages excluded with each length of continuous enrollment. (Figure 2 ). When stratified by sex, PrEP prevalence among the male population increased significantly over time (P trend < .001) with a very large increase in 2014 of 151.2 persons prescribed PrEP per million. Although PrEP prevalence among the female population also showed an increasing trend from 1.2 per million in 2010 to 3.7 per million in 2014 (P trend < .001), the overall uptake was much smaller than that in the male population (Figure 3) .
In our sensitivity analyses, we found that the percentages of persons excluded with HIV or hepatitis B infection were similar among our study population and the samples in the sensitivity analyses limited to a 3-, 6-, or 12-month continuous enrollment period before the index date (Supplementary Appendix Table 3 ), indicating a small misclassification bias due to lack of continuous enrollment criteria.
DISCUSSION
PrEP is a highly effective biomedical intervention that has changed the HIV prevention paradigm in the United States. In the current study, we found an increasing trend in the proportion of commercially insured persons prescribed TDF-FTC for PrEP from 2010 through 2014. In 2014, among 9375 PrEP users 97% were male, 98% resided in metropolitan areas, 43% resided in the West, and the mean age was 38 years. We observed an increasing trend in PrEP use among men, with an almost 27-fold increase in the number of users from 342 men in 2010 to 9137 in 2014. This is likely due to increased awareness of clinical providers, the public health workforce, and MSM of PrEP as an effective HIV prevention intervention that probably resulted from the widespread dissemination of CDC's 2014 PrEP clinical guidelines and resulting social media campaigns targeting MSM [16, 17] .
Only a small proportion of commercially insured women were PrEP users. Although a marked increasing trend in uptake was observed for men during the 5-year study period, the number of women who used PrEP remained very low during the study period. A recent study estimated the number of women aged 18-59 years at substantial risk of an HIV infection and who might benefit from PrEP to be 468 000, similar to the estimated number of at-risk MSM aged 18-50 years, 492 000 [18] . Our finding of low PrEP uptake by women highlights one of the key barriers encountered by clinicians of identifying women who have PrEP indications. Among US women, those with PrEP indications comprise <1%, compared with 25% for MSM [18] . Interventions are needed to increase PrEP use by women at substantial risk of acquiring an HIV infection.
Two previous studies have used a similar algorithm to assess PrEP uptake. One analysis used a large prescription claims database that included 39% of all US Truvada prescriptions from both private and public insurance claims and found an increasing trend in the number of persons prescribed PrEP, from 1511 in 2013 to 3920 in 2014 [19] . A second analysis of the New York state Medicaid database also found a 17% increase in the number of persons prescribed PrEP from July 2012-June 2013 to July 2013-June 2014 [17] . Compared with the previous studies that included public insurance claims, our analysis of private insurance claims showed a higher increase in PrEP uptake from 2013 (15.7 Weighted estimates were generated using national weighting variables included in the MarketScan database to generate national estimates of persons with commercial health insurance in the U.S. per million) to 2014 (75.4 per million), suggesting that persons with private insurance were more likely to receive PrEP. Similar to findings from our analysis, both of these studies found that most users were male and lived in metropolitan areas. Compared with those used in the previous studies, our data and methods have the advantage of generating nationally representative estimates of PrEP uptake among persons with commercial health insurance, and they include healthcare encounter information (eg, diagnostic and procedural codes) for all persons who were prescribed PrEP. These codes are necessary to discern whether Truvada was prescribed for PrEP, HIV treatment, or hepatitis B treatment. Our study has some limitations. We might have underestimated the number of persons prescribed PrEP. First, we assumed that persons who were prescribed TDF-FTC for ≤30 days used it for PEP, but our 30-day cutoff to distinguish PrEP from PEP may have excluded persons who used TDF-FTC as PrEP but discontinued it within 30 days. Second, we excluded persons who had active hepatitis B infection although some might have been prescribed TDF-FTC for PrEP. Third, TDF-FTC is the only medication approved by the Food and Drug Administration to be used for PrEP, but other antiretroviral medications might have been prescribed for PrEP. Fourth, a small number of PrEP users did not have weighting variables in the MarketScan database, and our national estimates were based on those with weighting variables.
The MarketScan database was a convenience sample of commercially insured persons, and our results might not be generalizable to the US population who were not commercially insured, such as persons who were uninsured or had government-sponsored health insurance [20] . The MarketScan database did not include information on enrollees' risk behaviors, such as engaging in risky sexual activities or injection drug use, which could be used to identify the highest-risk persons and their PrEP indications. Our methods may have resulted in a misclassification bias because our criteria did not include continuous enrollment of health plan enrollees during the study period. As a result, we might have errantly classified TDF-FTC use as PrEP because we did not have earlier claims information that would have indicated its use to treat HIV or hepatitis B infection. However, we did include all available claims data for 1 year before the TDF-FTC prescription, if available, to capture as much retrospective data as possible to compensate for this potential bias. Our sensitivity analyses demonstrated that our misclassification bias was probably small. In addition, another study that used a similar algorithm to estimate PrEP uptake validated their algorithm with a medical record review and found high sensitivity and specificity of their PrEP estimates using prescription claims data [21] .
The MarketScan database and our analytic methods provide the most feasible means to monitor PrEP uptake in the United States, and can be used to monitor progress in achieving goals of the recently updated National HIV/AIDS Strategy [22] . We found increasing numbers of male PrEP users during the study period, with the largest increase in number prescribed PrEP between 2013 and 2014, which is probably attributable to the publication and dissemination of CDC's PrEP guidelines for clinical providers. The large increases in PrEP use among men is encouraging, given that the largest proportion of new diagnoses have been among MSM. However, the estimated numbers of persons prescribed PrEP in our study and other studies were relatively small compared with the approximately 1.2 million persons who had indications for PrEP [18] . Our findings highlight gaps in our national PrEP implementation efforts. It is especially important to make PrEP accessible to persons in populations with high rates of newly diagnosed HIV infection, such as young black MSM and at-risk women. Targeting our public health efforts to increase PrEP uptake among persons in these populations will facilitate the impact of PrEP and help reduce the incidence of HIV infection in the United States.
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